IONS
Ionis Pharmaceuticals Inc
NASDAQ: IONS · HEALTHCARE · BIOTECHNOLOGY
$75.38
-0.87% today
Updated 2026-06-05
Market cap
$12.11B
P/E ratio
—
P/S ratio
11.44x
EPS (TTM)
$-2.01
Dividend yield
—
52W range
$35 – $87
Volume
1.8M
WallStSmart proprietary scores
31
out of 100
Grade: F
Strong Sell
Investment rating
6.7
Growth
B4.5
Quality
C2.0
Profitability
F5.7
Valuation
C+3/9
Piotroski F-Score
Weak
-0.2
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$101.38
+34.49%
12-Month target
—
—
Intrinsic (DCF)
$165.82
Margin of safety
+49.13%
9 Strong Buy12 Buy5 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Revenue growth 87.00% QoQ
+ 49.13% below intrinsic value
Risks
- Piotroski 3/9 — weak financial health
- Altman Z -0.22 — distress zone
- Thin margins at -30.90%
- Negative free cash flow $-814.58M
- Debt/equity 4.15x — high leverage
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM | 2026 (E) |
|---|---|---|---|---|---|---|
| Revenue | $587.37M | $787.65M | $705.14M | $944.00M | $1.06B | $0.9B |
| Net income | $-269.72M | $-366.29M | $-453.90M | $-381.00M | $-92.53M | — |
| EPS | — | — | — | — | $-2.01 | $-3.64 |
| Free cash flow | $-294.47M | $-335.52M | $-546.23M | $-320.03M | $-814.58M | — |
| Profit margin | -45.92% | -46.50% | -64.37% | -40.36% | -30.90% | — |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-06-01 | BERTHELSEN, SPENCER R | Sale | 8,000 | — |
| 2026-06-01 | BERTHELSEN, SPENCER R | Sale | 8,000 | $75.67 |
| 2026-05-14 | MONIA, BRETT P | Sale | 3,220 | — |
Peer comparison
Smart narrative
Ionis Pharmaceuticals Inc trades at $75.38. Our Smart Value Score of 31/100 indicates the stock is weak. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of -0.22, it sits in the distress. TTM revenue stands at $1.06B. with profit margins at -30.90%. Our DCF model estimates intrinsic value at $165.82.
Frequently asked questions
What is Ionis Pharmaceuticals Inc's stock price?
Ionis Pharmaceuticals Inc (IONS) trades at $75.38, on a P/S of 11.4x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Ionis Pharmaceuticals Inc overvalued?
Ionis Pharmaceuticals Inc carries a Smart Value Score of 31/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read. Our DCF puts intrinsic value at $165.82 versus the $75.38 price, a 49.1% margin of safety on a cash flow basis.
What is the price target of Ionis Pharmaceuticals Inc (IONS)?
The 12-month analyst consensus target is $101.38, about 34.5% above the current $75.38. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is the future stock price of IONS by 2030?
Our research-backed model puts the 2030 base case at $76.92, built from revenue projections, a growth-adjusted P/S multiple, net debt, and share dilution. It is a scenario rather than a prediction, and the bull and bear cases around it matter more than the single number when you are sizing a position.
What is the intrinsic value of Ionis Pharmaceuticals Inc (IONS)?
Our DCF model estimates intrinsic value at $165.82, a +49.1% margin of safety versus today's $75.38. Intrinsic value is what the projected cash flows are worth today. A positive reading means the price sits below that estimate, leaving a cushion if growth holds.
What is Ionis Pharmaceuticals Inc's revenue?
Ionis Pharmaceuticals Inc's trailing twelve-month revenue is $1.06B, and our model projects it reaching about $3.08B by 2030. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Ionis Pharmaceuticals Inc's Altman Z-Score is -0.22, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio11.44x
ROE-66.46%
Beta0.37
50D MA$74.95
200D MA$74.45
Shares out0.17B
Float0.16B
Short ratio—
Avg volume1.8M
Performance
1 week+0.00%
1 month+0.34%
3 months+4.62%
YTD-5.85%
1 year—
3 years—
5 years—